

09 July 2025 EMA/HMPC/239465/2024 Committee on Herbal Medicinal Products (HMPC)

European Union herbal monograph on Species pectorales Final

Initial assessment				
Discussion in Committee on Herbal Medicinal Products (HMPC)	September 2023			
	November 2023			
	July 2024			
	September 2024			
	November 2024			
Adopted by HMPC for release for consultation	20 November 2024			
Start of public consultation	15 December 2024			
End of consultation (deadline for comments) ¹	15 March 2025			
Re-discussion in HMPC	May 2025			
	July 2025			
Adoption by HMPC	09 July 2025			

Keywords	Committee on herbal medicinal products; HMPC; European Union herbal
	monographs; traditional herbal medicinal products; traditional use; herbal tea
	combinations for use in cough and cold; Species pectorales

¹ No comments were received during the period of public consultation. Therefore, the final monograph is published together with the final assessment report and list of references, without an 'overview of comments received during the public consultation'.



BG (bulgarski): Чаеви смеси за употреба при кашлица и настинки

CS (čeština): čajová směs pro použití při onemocnění horních cest dýchacích a kašli

DA (dansk): Urteteer ved hoste og forkølels

DE (Deutsch): Teemischungen zur Anwendung bei Husten und Erkältungen(DE)/Brusttee(AT)

EL (elliniká): Μείγματα φυτικών ειδών για έγχυμα/αφέψημα έναντι βήχα και κρυολογήματος

EN (English): Herbal tea combinations for use in cough and cold

ES (español):

ET (eesti keel):

FI (suomi): yskään ja vilustumiseen perinteisesti käytetyt yhdistelmäteevalmisteet

FR (français): espèces pectorales

HR (hrvatski): čajevi za kašalj i prehladu

HU (magyar): köhögés elleni teakeverék

IT (italiano): Specie composte per tisane ad azione lenitiva delle vie respiratorie superiori

LT (lietuvių kalba): Mišinys skirtas kosuliui ir peršalimui

LV (latviešu valoda): Tēja pret klepu un saaukstēšanos

MT (Malti): pjanti għall-użu tal-kundizzjonijiet tas-sider (sistema respiratorja)ta' riħ

NL (Nederlands): Pectorale kruiden

PL (polski): Mieszanki ziołowe wykrztuśne

PT (português): associações de substâncias vegetais para utilização em tisanas para a tosse e constipações

RO (română):

SK (slovenčina): prsná čajovina

SL (slovenščina): zdravilni čaji za kašelj in prehlad

SV (svenska): örtteer vid hosta och förkylning

IS (íslenska):

NO (norsk): urteteer ved hoste og forkjølelse

European Union herbal monograph on Species pectorales

1. Name of the medicinal product

To be specified for the individual finished product.

2. Qualitative and quantitative composition $^{2,\;3}$

Well-established use	Traditional use
	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC
	Herbal tea combinations containing several herbal substances out of the following list: Althaea officinalis L., radix Cetraria islandica (L.) Acharius s.l., thallus Filipendula ulmaria (L.) Maxim., flos Foeniculum vulgare Miller subsp. vulgare var. vulgare, fructus Glycyrrhiza glabra L.; Gycyrrhiza inflata Bat.; Glycyrrhiza uralensis Fisch., radix Plantago lanceolata L., folium Pimpinella anisum L., fructus Polygonum aviculare L., herba Primula veris L.; Primula elatior (L.) Hill, flos Salix [various species including S. purpurea L.; S. daphnoides Vill.; S. fragilis L.], cortex Sambucus nigra L., flos Thymus vulgaris L.; Thymus zygis L., herba Tilia cordata Miller; Tilia platyphyllos Scop.; Tilia x vulgaris Heyne, flos Verbascum thapsus L.; V. densiflorum Bertol. (V. thapsiforme Schrad); V. phlomoides L., flos
	i) Herbal substance Not applicable
	ii) Herbal preparations Combinations of comminuted herbal substances (see combinations table below)

² The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

³ The material complies with the Ph. Eur. monograph

	Althaeae radix	Anisi fructus	Filipendulae ulmariae flos	Foeniculi amari fructus	Lichen islandicus	Liquiritiae radix	Plantaginis Ianceolatae folium	Polygoni avicularis herba	Primulae flos	Salicis cortex	Sambuci flos	Thymi herba	Tilia flos	Verbasci flos	RANGE
Althaeae radix		+		+	+	+	+	+			+	+		+	5-25%
Anisi fructus	+					+						+	+		10-40%
Filipendulae ulmariae flos											+		+		20-30%
Foeniculi amari fructus	+				+	+	+	+	+		+	+	+	+	5-25%
Lichen islandicus	+			+		+	+	+	+			+	+	+	11.25- 15%
Liquiritiae radix	+	+		+	+		+	+			+	+		+	5-35%
Plantaginis lanceolatae folium	+			+	+	+		+			+	+		+	5-40%
Polygoni avicularis herba	+			+	+	+	+		+		+	+	+	+	10-15%
Primulae flos				+	+			+				+	+	+	6.25%
Salicis cortex											+		+		20-60%
Sambuci flos	+		+			+	+	+		+		+	+		5-50%
Thymi herba	+	+		+	+	+	+	+	+	+	+		+	+	10-40%
Tiliae flos		+	+	+	+			+	+	+	+	+		+	2-60%
Verbasci flos	+			+	+	+	+	+	+			+	+		3.75- 8%

A + indicates the evidence of traditional medicinal use of a certain combination.

Out of these documented combinations the combination partners for an application for a traditional herbal medicinal product may be chosen.

The number of active substances in an herbal tea combination is recommended to be limited to a maximum of 4. Further herbal substances may be added as excipients. Their number, amount and function should be justified.

The very right row indicates the traditional amount of the herbal substance in the combinations. The calculation is based on those combination partners only, which contribute to the plausibility of the traditional medicinal use. The amount in a traditional herbal medicinal product should be within this range. The sum of active ingredients should end up with 100%. Excipients are not considered in this range.

3. Pharmaceutical form

Well-established use	Traditional use
	Comminuted herbal substances as herbal tea for oral use.
	The pharmaceutical form should be described by

Well-established use	Traditional use
	the European Pharmacopoeia full standard term.

4. Clinical particulars

4.1. Therapeutic indications

Well-established use	Traditional use
	Traditional herbal medicinal product used to relieve cough and symptoms associated with common cold.
	The product is a traditional herbal medicinal product for use in the specified indication exclusively based upon long-standing use.

4.2. Posology and method of administration⁴

Well-established use	Traditional use
	Posology
	Herbal tea Single dose: 1.5–2 g of the herbal tea combination in 150 ml of boiling water as an herbal infusion 3 times daily. Daily dose: 4.5-6 g
	Combinations containing Althaeae radix, Anisi fructus, Foeniculi amari fructus, Lichen islandicus, Plantaginis lanceolatae folium, Polygoni avicularis herba, Primulae flos, Sambuci flos, Thymi herba, Tiliae flos, Verbasci flos The use in children under 12 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
	Combinations containing Filipendulae ulmariae flos, Liquiritiae radix, Salicis cortex The use in children and adolescents under 18 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
	Children between 4 and 12 years of age Combinations containing Althaeae radix and Foeniculi amari fructus, only. Single dose: 1 g of the herbal tea combination

 $^{^4}$ For guidance on herbal substance/herbal preparation administered as herbal tea or as infusion/decoction/macerate preparation, please refer to the HMPC 'Glossary on herbal teas' (EMA/HMPC/5829/2010 Rev.1).

Well-established use	Traditional use
	in 150 ml of boiling water as an herbal infusion 3 times daily. Daily dose: 3 g
	Duration of use
	If the symptoms persist longer than 1 week during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Method of administration
	Oral use.

4.3. Contraindications

Well-established use	Traditional use
	All combinations
	Hypersensitivity to the active substance(s).
	Combinations containing Anisi fructus, Foeniculi amari fructus, additionally
	Hypersensitivity to Apiaceae (Umbelliferae) family or to anethole.
	Combinations containing Foeniculi amari fructus additionally
	Hypersensitivity to mugwort polen, due to the cross reactivity with fennel.
	Combinations containing Filipendulae ulmariae flos, additionally
	Hypersensitivity to salicylates.
	Combinations containing Primulae flos, additionally
	Hypersensitivity to other Primulae species.
	Combinations containing Salicis cortex, additionally
	Hypersensitivity to salicylates or to other
	NSAIDs (e.g. history of angioedema, bronchial
	spasm, or chronic urticaria in response to
	salicylates or to other NSAIDs). Asthma due to
	sensitivity to salicylates. Active peptic ulcer
	disease. Third trimester of pregnancy. Glucose-
	6-phosphate dehydrogenase deficiency. Childre
	and adolescents under 18 years of age because of the risk of Reye's syndrome. Severe liver or
	renal dysfunction. Coagulation disorders.
	Combinations containing Thymi herba,

Well-established use	Traditional use
	additionally Hypersensitivity to other plants of the Lamiaceae (Labiateae) family.

4.4. Special warnings and precautions for use

Well-established use	Traditional use
	Combinations containing Salicis cortex Children and adolescents under 18 years of age due to the risk of Reye's syndrome.
	Combinations containing Althaeae radix, Lichen islandicus, Liquiritiae radix, Plataginis folium, Primulae flos, Sanbuci flos, Thymi herba or Verbasci flos If dyspnoea, fever or purulent sputum occurs during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Combinations containing Filipendulae ulmariae flos or Salicis cortex Concomitant use with salicylates and other NSAIDs is not recommended without medical advice. If fever exceeds 39°C, persists or is associated with severe headache, or if symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Combinations containing Foeniculi amari fructus The use in children between 4 and 12 years of age is not recommended if the daily intake of estragole exceeds the guidance value of 1.0 µg/kg bw, unless justified by a risk assessment based on adequate safety data.
	Combinations containing Liquiritae radix Patients taking liquorice medication should not take other liquorice containing products as serious adverse events may occur such as water retention, hypokalaemia, hypertension, cardiac rhythm disorders. Liquorice medication is not recommended to be used in patients affected by hypertension, kidney diseases, liver or cardiovascular disorders or hypokalaemia, as they are more sensitive to the adverse effects of liquorice.

Well-established use	Traditional use
	Combinations containing Primulae flos Caution is recommended in patients with gastritis or gastric ulcer.
	If the symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.

4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
	All combinations except for those containing Liquiritiae radix and/or Salicis cortex None reported.
	Combinations containing Liquiritiae radix Liquorice root may counteract antihypertensive action of prescribed medications. Not to be used concomitantly with diuretics, cardiac glycosides, corticosteroids, stimulant laxatives or other medications which may aggravate electrolyte imbalance.
	Combinations containing Salicis cortex Willow bark may increase the effects of anticoagulants such as coumarin derivatives.

4.6. Fertility, pregnancy and lactation

Well-established use	Traditional use
	All combinations except for those containing
	Foeniculi amari fructus, Liquiritiae radix and/or
	Salicis cortex
	Safety during pregnancy and lactation has not
	been established. In the absence of sufficient
	data, the use during pregnancy and lactation is
	not recommended.
	No fertility data available.
	Combinations containing Foeniculi amari fructus
	Safety during pregnancy and lactation has not
	been established (see sections 5.3 'Preclinical
	safety data' and 6 'Pharmaceutical particulars'
	regarding preclinical safety data related to the
	content of estragole).
	In the absence of sufficient data, the use during
	pregnancy and lactation is not recommended.

Well-established use	Traditional use
	There is evidence that trans-anethole is
	excreted in human breast milk.
	No fertility data available.
	Combinations containing Liquiritiae radix
	Studies in animals have shown reproductive
	toxicity.
	Not recommended (safety during pregnancy and
	lactation has not been established).
	No fertility data available.
	Combinations containing Salicis cortex
	The use during the first and second trimester of
	pregnancy and during lactation is not
	recommended. Salicylates cross the placenta
	and appear in breast milk.
	Contraindicated in the third trimester of
	pregnancy.
	No fertility data available.

4.7. Effects on ability to drive and use machines

Well-established use	Traditional use
	No studies on the effect on the ability to drive and use machines have been performed.

4.8. Undesirable effects

Well-established use	Traditional use
	Combinations containing Althaeae radix, Filipendulae ulmariae flos, Lichen islandicus, Liquiritiae radix, Plantaginis lanceolatae folium, Polygoni avicularis herba, Sambuci flos, Tiliae flos, Verbasci flos: None known. If adverse reactions occur, a doctor or a qualified health care practitioner should be consulted.
	Combinations containing Anisi fructus Allergic reactions to aniseed affecting the skin or the respiratory system have been reported. The frequency is not known. If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted. Combinations containing Foeniculi amari fructus

Well-established use	Traditional use
	Allergic reactions to fennel, affecting the skin or the respiratory system may occur. The frequency is not known. If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted.
	Combinations containing Primulae flos Allergic reactions may occur. The frequency is not known. If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted.
	Combinations containing Salicis cortex Allergic reactions such as rash, pruritis, urticaria, asthma, exanthema and gastrointestinal symptoms such as, nausea, vomiting, abdominal pain, diarrhea, dyspepsia, heartburn, may occur. The frequency is not known. If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted.
	Combinations containing Thymi herba Gastric disorders may occur. The frequency is not known. If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted.

4.9. Overdose

Well-established use	Traditional use
well-established use	All combinations except for those containing Liquiritiae radix and/or Primulae flos No case of overdose has been reported. Combinations containing Liquiritiae radix Cases of overdose have been reported with prolonged use (more than 4 weeks) and/or intake of high amount of liquorice, with symptoms such as water retention, hypokalaemia, hypertension, cardiac rhythm disorders, hypertensive encephalopathy.
	Combinations containing Primulae flos Overdose may lead to stomach upset, vomiting or diarrhoea.

5. Pharmacological properties

5.1. Pharmacodynamic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC.

5.2. Pharmacokinetic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC.

5.3. Preclinical safety data

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC, unless necessary for the safe use of the product.
	Combinations containing Filipendulae ulmariae flos, Lichen islandicus, Polygoni avicularis herba, Primulae flos, Salicis cortex, Sambuci flos Tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed.
	Combinations containing Althaeae radix, Plantaginis lanceolatae folium, Tiliae flos Adequate tests on genotoxicity have not been performed. Tests on reproductive toxicity and carcinogenicity have not been performed.
	Combinations containing Thymi herba, Verbasci flos Adequate tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed.
	Combinations containing Anisi fructus An aniseed extract prepared with water was tested in an Ames test on Salmonella typhimurium strains TA98, TA100, TA102 and turned out as negative.
	Results from non-clinical studies showed a weak mutagenic potential of anethole. Anethole and its metabolites are unlikely to be genotoxic in vivo. The genotoxic risk related to estragole is not

Well-established use	Traditional use
	considered to be relevant in the specified conditions of use (short term use in adolescents, adults and elderly) due to the small amount present in herbal infusions prepared from aniseed.
	Combinations containing Foeniculi amari fructus A fennel aqueous extract was tested in an Ames test on Salmonella typhimurium strains TA98, TA100 and turned out as negative. Results from studies carried out in laboratory animals showed a weak mutagenic activity of anethole. Several studies have shown the carcinogenic effects of estragole and some of its metabolites in mice (liver tumours) and displayed suggestive but indirect evidence of carcinogenicity in rats. Estragole is considered a genotoxic carcinogen in rodents (see section 6 'Pharmaceutical particulars' for further details). An aqueous extract of fennel seeds given daily to 24 female BALB/c mice from day 6 to day 15 of pregnancy showed a dose-dependent teratogenic effect. The embryotoxic effect resulted in morphological changes, skeletal disorders, and cellular alterations. Adequate tests on reproductive toxicity have not been performed.
	Combinations containing Liquiritiae radix The risks related to Liquiritiae radix as described in the single monograph are not considered in the present monograph because they are not considered to be relevant in the specified conditions of use due to the small amount present in herbal infusions prepared with such
	herbal substance.

6. Pharmaceutical particulars

Well-established use	Traditional use
	Combinations containing Foeniculi amari fructus
	In the general population, exposure to estragole
	should be kept as low as practically achievable.
	In pregnant and breast-feeding women, the daily
	intake of estragole has to be below 0.05
	mg/person per day. In children below 12 years of
	age, the daily intake of estragole has to be below

Well-established use	Traditional use
	1.0 μg/kg bw.

7. Date of compilation/last revision

09 July 2025